Absci Corporation (ABSI)
NASDAQ: ABSI · Real-Time Price · USD
9.49
-0.25 (-2.57%)
At close: Sep 28, 2026, 4:00 PM EDT
9.50
+0.01 (0.11%)
After-hours: Sep 28, 2026, 7:50 PM EDT
Absci Employees
Absci had 140 employees as of December 31, 2025. The number of employees decreased by 17 or -10.83% compared to the previous year.
Employees
140
Change (1Y)
-17
Growth (1Y)
-10.83%
Revenue / Employee
$11,150
Profits / Employee
-$864,836
Market Cap
1.63B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 140 | -17 | -10.83% | 140 | 0 |
| Dec 31, 2024 | 157 | 1 | 0.64% | 156 | 1 |
| Dec 31, 2023 | 156 | -37 | -19.17% | 155 | 1 |
| Dec 31, 2022 | 193 | -19 | -8.96% | 193 | 0 |
| Dec 31, 2021 | 212 | 110 | 107.84% | 211 | 1 |
| Sep 30, 2021 | 207 | 105 | 102.94% | 207 | 0 |
| Jun 30, 2021 | 169 | - | - | 169 | 0 |
| Mar 31, 2021 | 102 | - | - | 102 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Novavax | 749 |
| Immunocore Holdings | 524 |
| Intellia Therapeutics | 377 |
| Syndax Pharmaceuticals | 298 |
| Stoke Therapeutics | 170 |
| Zenas BioPharma | 167 |
| Septerna | 123 |
| Nanobiotix | 100 |
ABSI News
- 4 days ago - Absci announces preliminary details for Phase 2 Storyline trial of ABS-201 - TheFly
- 4 days ago - Absci Announces Preliminary Details for Phase 2 STORYLINE™ Trial of AI-Designed Antibody ABS-201™ for Endometriosis - GlobeNewsWire
- 12 days ago - Absci Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 13 days ago - Absci Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 19 days ago - Absci initiated with an Outperform at LifeSci Capital - TheFly
- 20 days ago - Absci price target raised to $15 from $13 at BTIG - TheFly
- 27 days ago - Absci to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 6 weeks ago - Absci reports Q2 EPS (21c), consensus (20c) - TheFly